Skip to content
BALCAO · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Synlogic, Inc. SYBX

13 fiscal years on record · USD · FY2025 reported · SEC filings only
$0
▼ 100.0% YoY
$-1.0M
$-4.4M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Growth

USD 0.00
Revenue, FY2025 · full 13-year series below
Revenue $M Net income $M
FY2025 · Revenue 0.0 · Net income -1.0
-25.0M-50.0M
20132016201920222025
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

·
Operating margin Net margin
FY2023 · Operating -1636.3%
-5000%-10000%
201320192025
ROE
FY2025 · ROE -8.2%
-200%-400%
201320192025
Three returns, three denominators.

Each USD of equity lost 8 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -4.4
-30M-60M
201320192025

Total assetsUSD 15.4M
EquityUSD 11.9M
CashUSD 14.7M
Current ratio4.30×

Equity funds 77% of total assets.

The 13-year record

13 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
SYBX, 13-year financial record
Metric 2025202420232022202120202019201820172016201520142013
Revenue $B0.00.00.00.00.00.00.00.00.00.0◌◌◌
Operating income $B−0.0−0.0−0.1−0.1−0.1−0.1−0.1−0.1−0.0−0.0◌◌◌
EBITDA $B−0.0−0.0−0.1−0.1−0.1−0.1−0.1−0.0−0.0−0.0◌◌◌
Income tax $B0.00.00.00.00.00.00.00.0◌0.00.00.0◌
Net income $B−0.0−0.0−0.1−0.1−0.1−0.1−0.1−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.0−0.0−0.1−0.1−0.1−0.0−0.1−0.0−0.0−0.0−0.0−0.0−0.0
EPS, diluted $−0.08−1.92−9.42−13.83−1.09−1.65−1.70−2.03−6.00−1.26−5.85−291.00−4408.65
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend—————————————
ROE %−8.2−102.6−106.2−57.6−46.2−43.5−36.6−46.3−86.3−442.1———
Shares out B0.010.010.010.070.070.040.030.030.020.000.020.00◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 50 reconciliationsAUDITED

Reconciled in 13 of the 13 fiscal years we could check. 14 checks were skipped: the balance sheet is not tagged before 2014. Six checks were skipped: EPS is not tagged before 2013.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onOTC market
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2013

Share this section

Download image